DISQVER® is a NGS (next-generation sequencing) based pathogen detection platform by Noscendo integrating a CE-IVD software solution for sensitive, reliable and fast pathogen identification and assessment. DISQVER® allows a hypothesis free detection of bacteria, fungi, DNA viruses and parasites from a single standard blood draw without prior cultivation or knowledge about the aetiology of the infection. DISQVER® uses proprietary and continuously refined databases as well as relevance assessment methods allowing us to make a precise differentiation of commensals, contamination and infection.
Cell-free DNA, as an abundant biomarker, from a standard blood draw is used for pathogen detection
Data is prepared using highly sensitive genomic workflow on newest sequencing technology
Advanced proprietary algorithms and continuously refined clinical grade databased are used to analyse sequencing data
An analytical report containing all relevant pathogens detected in the patient’s sample is generated and provided to you in real time by the „NOS-Portal“
We are here to give you the ability to help patients get the best possible care.
Offering DISQVER® tailored to your needs. We give you an option to use DISQVER® in a direct and easy way: the Send-In model. We are taking care of logistics, analysis and result communication so that you can focus on solving your daily challenges.
We partner with your laboratory to bring DISQVER® even closer to the patient: the Enabling model. Enabling your laboratory to offer DISQVER® reduces turn around times, and supports you within your familiar information paths. New, unique ways of pathogen detection embedded in your known environment. Please contact us if you need further information on Noscendo services, or if you are interested to test or implement Noscendo diagnostics in your hospital, so we can set up a service tailored to your needs.
Medical Express - Overnight
Send in Noscendo laboratory
No own sequencing device necessary
Easy to use for small sample numbers
Optimal cost benefit ratio for small sample numbers
Enabling your own laboratory
Full cost control of the entire lab process
Optimal utilisation of your sequencing device
Embedded into your laboratory environment
Same reliability independent of the used model
COVID-19 infection can cause a number of complications such as hypoxia, acute respirato- ry distress syndrome (ARDS), thromboembolic disease, multi-organ failure and in some ca- ses secondary bloodstream infections. These may be pre-existing (co-infections) or occur during COVID-19 disease (secondary infections). Concomitant microbial infections caused by bacteria, fungi or viruses are common in viral respiratory infections and cause high mor- bidity and mortality.
Infections and especially bloodstream infections are a major cause of complications for oncological and haematological patients during or after therapy. They are associated with increased morbidity and mortality. Previous methods for detecting bloodstream infections in these indications have significant disadvantages. The DISQVER® pathogen test offers a solution to fill the gap left by existing tests. With its open-ended approach without hypotheses, the innovative bioinformatics of DISQVER® enables reliable, efficient and rapid identification of pathogens from patient blood. DISQVER® represents a new generation in pathogen diagnostics and enables a completely new perspective in the treatment of bloodstream infections.
Systemic bloodstream infections, caused by e.g. peritonitis, pneumonia, after organ trans- plantation or even sepsis, are associated with high case numbers, high mortality and enormous costs. The DISQVER® pathogen test offers a solution to close the gap of existing tests. With an open-ended and hypothesis-free approach, DISQVER® with its combination of NGS and innovative bioinformatics enables reliable, efficient and rapid identification of pathogens from patient blood. DISQVER® represents a new generation of pathogen diagnostics and enables a completely new perspective in the treatment of bloodstream infections.